Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 in LRRK2-Associated Parkinson's Disease
NCT06602193Phase 2Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB122 225 mg with BIIB122 Matching Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at 12 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06602193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602193.